leading digital health companies glp-1 Dr. Craig Primack talks Hims & Hers launching its own offering as demand rises GLP-1 Business Report for Healthtech
Description
Full article linked below.
The incretin system has become an important target in the treatment of type 2 diabetes in recent years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose-lowering effects
Smaller portions that feel manageable
Healthcare professionals are issuing warnings for individuals taking GLP-1 medications to monitor their hydration levels and be vigilant for heat-related symptoms as
Very impressed and will certainly continue to take them
